Affimed (NASDAQ: AFMD)
Affimed Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Affimed Company Info
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
News & Analysis
Why Shares of Affimed Fell Thursday
The clinical-stage biotech focuses on immuno-oncology therapies.
Why Affimed Stock Plummeted by Over 16% Today
An analyst's downgrade brings out the bears for the European cancer treatment developer.
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Why Affimed Stock Is Heating Up Today
The biotech's experimental blood cancer treatment could be a major advancement.
3 Under-the-Radar Biotech Stocks That Will Zoom Higher
Finding stocks with significant upside before the rest of the market sees what's happening can be highly profitable.
3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now.
Why Affimed Stock Is On Fire Today
The biotech's early-stage trial results are turning heads on Wall Street today.
Why Affirmed Stock Was Up More Than 12% Wednesday
Positive trial results regarding the company's pipeline are buoying the stock's price.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.